Original vineyard study · Cabernet Sauvignon; a 2022 field trial reported in the 2025 paper; four replicates per treatment.
DOCUMENTED APPLICATION
The highest reported field inhibition was 71.94%; two other BJ-3 treatments were 65.66% and 54.83%.
TECHNICAL SCOPE
Treatment-specific results from one trial. They do not establish effectiveness across all cultivars, countries or trunk-disease complexes.




